Loading clinical trials...

Evolution of Lesions in Repeated Biparametric Prostate Magnetic Resonance Imaging | Clinical Trials | Clareo Health

RECRUITINGNA

Evolution of Lesions in Repeated Biparametric Prostate Magnetic Resonance Imaging

A Prospective Study of the Evolution of Lesions in Repeated Biparametric Prostate Magnetic Resonance Imaging

NCT07369570•University of Eastern Finland

Summary

The goal of this clinical trial is to prospectively investigate the evolution of lesions in biparametric magnetic resonance imaging (bpMRI) of the prostate in men with no clinically significant prostate cancer (csPCa) in their initial biopsy. The main questions it aims to answer are: Does lesion progression in bpMRI predict a diagnosis of csPCa in per-protocol follow-up biopsies? What are the radiological and clinical risk factors for csPCa in per-protocol follow-up biopsies?

Eligibility

Age

40 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Suspicion of a local prostate cancer
•Patient have 1-2 PI-RADS 3-5 lesion/lesions in biparametric prostate MRI, with no ISUP 2-5 prostate cancer in an initial systematic or lesion-targeted (at least two biopsy cores per lesion) biopsy
•Prostate biopsies can be taken via transrectal approach in an outpatient clinic
•An estimated life expentancy exceeding 10 years
•The patient is cooperative, fluent in Finnish and understands the significance of the study
•The patient signs an informed consent form approved by the ethics committee.

Exclusion Criteria

•The patient had undergone prostate biopsies prior to the biopsies that led to recruitment for the current study.
•Seriuos infectious or non-infectious complication after initial biopsy
•Deep immunosuppression due to organ transplant, hematologic disease, or related causes.
•Any treatment given for prostate cancer diagnosed in initial biopsy
•Hip prosthesis or any other object in the pelvic area that affects high-quality MRI
•Claustrophobia or other absolute or relative contraindication for high-quality MRI

Locations (1)

Kuopio University Hospital

Kuopio, Finland

Key Dates

Start Date

February 23, 2026

Primary Completion Date

December 31, 2027

Completion Date

December 31, 2037

Last Updated

February 24, 2026

Enrollment

100

ESTIMATED participants

Conditions

Prostate Cancer (Diagnosis)

Interventions

MRI

DIAGNOSTIC_TEST

Contacts

Juha Knaapila, MD, PhD

CONTACT

+358447178679 juha.knaapila@pshyvinvointialue.fi

PSMA PET for Surveillance After Focal Therapy

NCT07115914

Prostate Cancer (Adenocarcinoma)Prostate Cancer (Diagnosis)+1 more

View study

RECRUITINGPHASE1

Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe

NCT07271017

Prostate Cancer (Diagnosis)

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 24, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Evolution of Lesions in Repeated Biparametric Prostate Magnetic Resonance Imaging

Inclusion Criteria

Exclusion Criteria

PSMA PET for Surveillance After Focal Therapy

Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe

Virtual Biopsy of Prostate Cancer Using PSMA PET and AI

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

Intratumoral Heterogeneity on [18F]PSMA and [18F]FDG PET/CT in Predicting Invasion and Prognosis of Prostate Cancer

Stockholm3 Validation Study in a Multi-Ethnic Cohort